Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

44.74 +2.17 (+5.11%)
Streaming Delayed Price Updated: 12:07 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corp

< Previous 1 2 3 4 Next >
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
Blueprint Medicines met all its goals, but the results paled from an earlier study. 
Via Investor's Business Daily
Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study
Blueprint Medicines (NASDAQ: BPMC) announced positive top-line results from the Part 2 of PIONEER clinical trial of AYVAKIT (avapritinib) in patients with non-advanced systemic mastocytosis (SM). 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Blueprint Medicines: Q2 Earnings Insights
  Blueprint Medicines (NASDAQ:BPMC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
4 Analysts Have This to Say About Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
A Preview Of Blueprint Medicines's Earnings
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
3 Biotech Stock Picks From This Wedbush Analyst
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June. 
Via Benzinga
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. The USD Fund VIII has $2.5 billion and the first... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
 
Via Benzinga
Blueprint Medicines: Q1 Earnings Insights
Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Blueprint Medicines
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Upgrades 
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know
SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32%... 
Via Benzinga
10 Biggest Price Target Changes For Monday
RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading. 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
 
Via Benzinga
What You Missed On Wall Street On Thursday
Here are our top five lists with the news and calls moving stocks, that you better not have missed yesterday... 
Via Talk Markets
Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug
The FDA had a suggestion for Blueprint's midstage systemic mastocytosis test. 
Via Investor's Business Daily
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
Bristol Myers is moving deeper into the targeted oncology space. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading. 
Via Benzinga
What 3 Analyst Ratings Have To Say About Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Preview: Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.